SYRE Spyre Therapeutics
- 23.860
- +0.730+3.16%
- 23.860
- 0.0000.00%
Spyre Therapeutics News
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market
Spyre Therapeutics Weakness After Teva Data a Buying Opportunity, Says BTIG
JonesTrading Initiates Spyre Therapeutics at Hold
Spyre Therapeutics Analyst Ratings
JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating
Spyre Therapeutics Announces Grants of Inducement Awards
Express News | Spyre Therapeutics Inc - Interim Data for Spy002 Molecules Expected in Q2 2025
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Jefferies, Goldman Sachs Among Managers for Spyre Offering >SYRE
Spyre Offering Expected to Close on or About November 20 >SYRE
Spyre: Underwritten Offering of 7,275,000 Shares Priced at $27.50 Each >SYRE
Express News | Spyre Therapeutics Inc Shares Down 1.2% in Late Trade at $28.33 Following Filing for Stock Offering
Spyre Therapeutics Faces Internal Control Challenges
Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants
No Data